Partial encapsulation of stents

Information

  • Patent Grant
  • 10213328
  • Patent Number
    10,213,328
  • Date Filed
    Thursday, December 12, 2013
    11 years ago
  • Date Issued
    Tuesday, February 26, 2019
    5 years ago
Abstract
A method of making an implantable medical device includes extruding a first ePTFE tube and a second ePTFE tube, cutting a plurality of slits in the first ePTFE tube, positioning a radially expandable support layer between the first and second ePTFE tubes so that the slits span portions of the support layer, and laminating the first ePTFE tube to the second ePTFE tube through openings in the support layer.
Description
BACKGROUND

The present invention relates generally to the field of medical devices, and more particularly, to encapsulation of stents.


Stents and related endoluminal devices are currently used by medical practitioners to treat portions of the vascular system that become so narrowed that blood flow is restricted. Stents are tubular structures, usually of metal, which are radially expandable to hold a narrowed blood vessel in an open configuration. Such narrowing (stenosis) occurs, for example, as a result of the disease process known as arteriosclerosis. Angioplasty of a coronary artery to correct arteriosclerosis may stimulate excess tissue proliferation which then blocks (restenosis) the newly reopened vessel. While stents are most often used to “prop open” blood vessels, they can also be used to reinforce collapsed or narrowed tubular structures in the respiratory system, the reproductive system, biliary ducts or any other tubular body structure. However, stents are generally mesh-like so that endothelial and other cells can grow through the openings resulting in restenosis of the vessel.


Polytetrafluoroethylene (PTFE) has proven unusually advantageous as a material from which to fabricate blood vessel grafts or prostheses used to replace damaged or diseased vessels. This is partially because PTFE is extremely biocompatible causing little or no immunogenic reaction when placed within the human body. This is also because in its preferred form, expanded PTFE (ePTFE), the material is light and porous and is potentially colonized by living cells becoming a permanent part of the body. The process of making ePTFE of vascular graft grade is well known to one of ordinary skill in the art. Suffice it to say that the critical step in this process is the expansion of PTFE into ePTFE following extrusion from a paste of crystalline PTFE particles. Expansion represents a controlled longitudinal stretching in which the PTFE is stretched up to several hundred percent of its original length. During the expansion process fibrils of PTFE are drawn out of aggregated PTFE particle (nodes), thereby creating a porous structure.


If stents could be enclosed in ePTFE, cellular infiltration could be limited, hopefully preventing or limiting restenosis. Early attempts to produce a stent enshrouded with ePTFE focused around use of adhesives or physical attachment such as suturing. However, such methods are far from ideal, and suturing, in particular, is very labor intensive. More recently, methods have been developed for encapsulating a stent between two tubular ePTFE members whereby the ePTFE of one-member contacts and bonds to the ePTFE of the other member through the openings in the stent. However, such a monolithically encapsulated stent tends to be rather inflexible. In particular, radial expansion of the stent may stress and tear the ePTFE. There is a continuing need for a stent that is encapsulated to prevent cellular intrusion and to provide a smooth inner surface blood flow and yet still capable of expansion without tearing or delaminating and is relatively more flexible.


BRIEF SUMMARY

The present invention is directed to encapsulated stents wherein flexibility of the stent is retained, despite encapsulation.


It is an object of this invention to provide a stent device that has improved flexibility, yet maintains its shape upon expansion.


It is also an object of this invention to provide a stent encapsulated to prevent cellular infiltration wherein portions of the stent can move during radial expansion without stressing or tearing the encapsulating material.


These and additional objects are accomplished by an encapsulation process that leaves portions of the stent free to move during expansion without damaging the ePTFE covering. The most basic form of this invention is produced by placing a stent over an inner ePTFE tube (e.g., supported on a mandrel) and then covering the outer surface of the stent with an outer ePTFE tube into which slits have been cut. The outer ePTFE tube is then laminated to the inner ePTFE tube through openings in the stent structure to capture the stent. By selecting the size and location of the slits, it is possible to leave critical parts of the stent unencapsulated to facilitate flexibility and expansion. Not only does the slit prevent capture of the underlying ePTFE, it forms a focal point for the ePTFE to flex. A more complex form of the process is to place over the stent an ePTFE sleeve into which apertures have been cut. This “lacey” outer sleeve leaves portions of the stent exposed for increased flexibility and for movement of the stent portions during expansion without damaging the ePTFE. Although a single stent can be used, these approaches lend themselves to use of a plurality of individual ring stents spaced apart along an inner ePTFE tube and covered by a “lacey” ePTFE sleeve.


In the present invention, individual ring stents are partially encapsulated using the procedure outlined above. Preferably, ring stents of zigzag sinusoidal structure are placed “in phase” (e.g., peaks and valleys of one stent aligned with those of a neighboring stent) on the surface of a tubular ePTFE graft supported by a mandrel. A sleeve of ePTFE is cut using CO2 laser so that openings are created, resulting in a “lacey” pattern. This “lacey” sleeve is then placed over the ring stents. The resulting structure is then subjected to heat and pressure so that regions of ePTFE become laminated or fused together where the lacey sleeve contacts the tubular graft. In addition, the ends of the stent can be completely encapsulated, by known methods, to stabilize the overall structure.


A more complete understanding of the encapsulation process will be afforded to those skilled in the art, as well as a realization of additional advantages and objects thereof, by a consideration of the following detailed description of the preferred embodiment. Reference will be made to the appended sheets of drawings which will first be described briefly.





BRIEF SUMMARY OF THE DRAWINGS


FIG. 1 is a perspective view of a tubular ePTFE member with individual ring stents arranged thereon.



FIG. 2 is a perspective view of the “lacey” sleeve of the present invention.



FIG. 3 is a perspective view of the sleeve in FIG. 2 placed over the structure of FIG. 1.



FIG. 4 is a perspective view of one configuration of the slitted sleeve of the present invention with longitudinally oriented slits.



FIG. 5 is a perspective view of a second configuration of the slitted sleeve of the present invention with circumferentially oriented slits.



FIG. 6 is a perspective view of a third configuration of the slitted sleeve as it is placed over the structure in FIG. 1.



FIG. 7 is a perspective view of an alternate embodiment of the present invention.





DETAILED DESCRIPTION

The present invention satisfies the need for an encapsulated stent device to prevent restenosis that is flexible upon expansion and contraction so that the general structural form is retained. This is accomplished encapsulating a stent or a plurality of stent rings using an ePTFE covering into which openings have been cut.


Referring now to the drawings, in which like reference numbers represent similar or identical structures throughout, FIG. 1 illustrates an initial step in constructing the partially encapsulated stent of the present invention. A tubular ePTFE graft 20 is placed over a mandrel for the assembly of a device 10 (FIG. 3). A stent is then placed over the graft 20. In a preferred embodiment, as shown in FIG. 1, a series of zigzag sinusoidal ring stents 30 are placed over the outer surface of the graft 20. Alternatively, one or more stents wherein each stent comprises more than one ring or hoop (e.g., where the rings are helically connected) can be used. The ring stents 30 can be made of any material but a preferred material is metal. The zigzag ring stents 30 may be assembled “in phase” with each adjacent ring stent having peaks and valleys aligned. Alternatively, the individual stents 30 can be “out of phase” to different degrees. It will be apparent that the phase relation of adjacent stents 30 will alter the lateral flexibility as well as the longitudinal compressibility of the structure. The phase relationship can be varied along the length of the device 10, thereby altering the physical properties in different portions of the device 10. Having individual ring stents 30, as opposed to a single tubular stent, provides the advantage that the periodicity, or the number and precise shape of the zigzags per ring, can readily be varied along the length of the graft to influence flexibility and stability properties of the structure. Also, spacing of the individual stents (number of stents per unit length) as well as the phase relationship of stent to stent can be varied to produce stent grafts with desired properties. By placing the ring stents 30 over the outer surface of the tubular ePTFE graft 20, the resulting structure has an inner (luminal) surface that is completely smooth to facilitate the flow of blood. However, there may be instances where the ring stents 30 or other tubular stents are advantageously placed in contact with the inner graft surface or on both the inner and outer surfaces, as one of ordinary skill in the art will readily appreciate.



FIG. 2 shows the structure of a “lacey” graft comprising a sleeve of ePTFE 40 into which apertures have been cut. This “lacey” graft 40 is placed over the ring stents 30 in the preferred embodiment. The “lacey” graft 40 is created by cutting openings 44 in a tubular ePTFE graft 42. The openings 44 were cut into the sleeve by a CO2 laser, although any other cutting technology could readily be employed. The “lacey” graft 40 is slid over the ring stents 30 and the underlying tubular graft 20 to form the preferred structure 10 shown in FIG. 3. The structure 10 is then exposed to heat and pressure, such as that caused by wrapping with PTFE tape followed by heating in an oven, thereby causing the ePTFE regions of the “lacey” graft 40 to fuse or laminate to the tubular graft 20 wherever they touch each other. It should be appreciated that the circumferential sections of ePTFE 46 that are placed over the ring stents 30 can encompass many different designs. As illustrated, a sleeve 42 with openings 44 cut out is one way of accomplishing the goal of flexibility and stability. The openings 44 between the rings of ePTFE 46 can be altered to control the degree of flexibility and stability desired. In the preferred embodiment shown in FIG. 3, the “lacey” graft 40 forms a number of circumferential sections 46, which are intended to cover a portion of the circumference of each ring stent 30, leaving the ends of the zigzags uncovered. By circumferentially covering only a portion of each ring stent 30, the maximum amount of lateral flexibility is provided.


However, circumferentially covering the individual ring stents 30 without any longitudinal support would result in a structure with little longitudinal strength and stability that would be prone to “telescoping”. Thus, the longitudinal sections 48 that connect the rings of ePTFE 46 are important, because the longitudinal sections 48 are completely laminated to the underlying graft 20 and act as “anti-compression” devices by resisting the shortening of the structure 10 (the double thickness of ePTFE resists telescoping of the longitudinal sections 48). The width of the circumferential sections 46 and the longitudinal sections 48 control longitudinal strength and stability versus lateral flexibility. By adjusting these parameters, grafts can be made more or less flexible with greater or lesser anti-compression strength. In the preferred embodiment, four longitudinal sections 48 are formed and the ends of the structure 10 are completely encapsulated for greater stability. Of course, a larger number of longitudinal sections 48 could be formed. Also the longitudinal sections 48 may themselves zigzag or may be helically arranged depending on how the openings 44 are cut into the sleeve 42. Each different structure will possess different properties. Similarly, the circumferential sections 46 can have different forms and may be undulating. There is nothing to preclude a covering with a more complex pattern where circumferential sections and longitudinal sections are difficult to discern or are even nonexistent.


A second embodiment of the present invention can be seen in FIGS. 4-6. Instead of having a “lacey” graft structure, a slitted outer sleeve is used to provide partial encapsulation of the stent, the slits providing flexibility to the structure, allowing the stent to expand and retract more readily. In FIG. 4, four longitudinal slits 52 run the length of the stent, leaving 5 to 10 mm of uncut sleeve 50 at the ends. The slits are formed at 0°, 90°, 180°, and 270°, and are oriented to pass over a peak portion of each zigzag ring stent 30 (FIG. 6). FIG. 5 shows circumferential slits 62, wherein slits are cut circumferentially around the sleeve 60 at spaced intervals, preferably to coincide with a stent ring. At each radial section, two slits are cut around the circumference at evenly spaced intervals. In a first radial section, the slits span from 0° to 90° and from 180° to 270°. Each successive radial section has a pair of slits which are offset 90° from the previous pair. Thus, a second radial section will have slits spanning from 90° to 180° and from 270° to 0°. Beside the configurations shown in FIGS. 4 and 5, a number of other slit configurations are possible, including diagonal and sinusoidal as will be appreciated by one skilled in the art. As shown in FIG. 6, a sleeve 70 is placed over the ring stents 30 and the underlying tubular graft 20 to form a new structure 80. The longitudinal slits 72, which are cut into sleeve 70, differ from the slits 52 shown in FIG. 4 in that they do not span the length of the structure 80 and are staggered around the circumference of the sleeve 70. Ideally, the slits are aligned over the peaks in the zigzag ring stents 30. Once the slits 72 are cut into the sleeve 70 using any of the known methods, the structure 80 is exposed to heat and pressure, such as that caused by wrapping with ePTFE tape and heating in an oven, thereby causing the ePTFE regions of the slitted graft 70 to fuse or laminate to the tubular graft 20. The slits 72 in the slitted outer sleeve 70 can be formed by using a CO2 laser, razor blade or any other suitable technique known in the art. The slits enhance the flexibility of the encapsulated structure and allow radial expansion without tearing of the ePTFE. In addition, a plurality of slits help the expanded graft to grip onto the vessel wall. This is particularly important where an encapsulated stent graft is spanning a region of damaged or weakened vessel as in an aneurysm. Further, during the healing process tissues readily grow into the slits further anchoring the graft to the vessel wall.


An advantage that cutting slits into an ePTFE sleeve offers is that it is somewhat easier to manufacture than is the “lacey” graft. Because no material is removed the sleeve is somewhat stronger than a “lacey graft”. There are a multitude of configurations possible, including cutting the slits in asymmetric fashion to achieve desired results, such as using radial, longitudinal and diagonal cuts simultaneously. Moreover, a greater number of slits can be cut into a region of the structure in which greater expansion is desired.


Although the above examples are described with the “lacey” and slitted grafts being placed over a stent which is itself placed over a tubular graft, this orientation can be readily reversed. That is, the “lacey” or slitted grafts can be placed on a mandrel; a stent or stents can be then placed over the “lacey” or slitted grafts, and a tubular graft can be then placed over the stent or stents. This results in a structure wherein part or much of the luminal surface is provided by the outer graft, providing superior healing as only a single layer of ePTFE would separate body tissues from the blood. Moreover, a structure with two “lacey” or slitted grafts is possible. As shown in FIG. 7, the openings 112 in the outer graft 110 are arranged out of phase with the openings 122 in the inner graft 120. Such a configuration provides a blood tight structure wherein a majority of the final surface area of the device 100 comprises a single layer separating body tissue from the circulating blood. Also, the areas occupied by the stent(s) 30 and by overlap between the two grafts 110, 120 present a barrier to cellular infiltration. The described structure has the advantage of a smaller profile when compressed because the overall amount of ePTFE is reduced. In a further embodiment, a combination of the “lacey” graft and slitted graft could be produced.


Having thus described preferred embodiments of the partial encapsulation of stents, it will be apparent by those skilled in the art how certain advantages of the present invention have been achieved. It should also be appreciated that various modifications, adaptations, and alternative embodiments thereof may be made within the scope and spirit of the present invention. For example, zigzag stent rings have been illustrated, but it should be apparent that the inventive concepts described above would be equally applicable to sinusoidal and other stent designs. Moreover, the words used in this specification to describe the invention and its various embodiments are to be understood not only in the sense of their commonly defined meanings, but to include by special definition in this specification structure, material or acts beyond the scope of the commonly defined meanings. Thus, if an element can be understood in the context of this specification as including more than one meaning, then its use in a claim must be understood as being generic to all possible meanings supported by the specification and by the word itself. The definitions of the words or elements of the following claims are, therefore, defined in this specification to include not only the combination of elements which are literally set forth, but all equivalent structure, material or acts for performing substantially the same function in substantially the same way to obtain substantially the same result. The described embodiments are to be considered illustrative rather than restrictive. The invention is further defined by the following claims.

Claims
  • 1. An implantable medical device, comprising: an elongate inner tube of expanded polytetrafluoroethylene;an elongate outer sleeve of expanded polytetrafluoroethylene having a length, the outer sleeve including a plurality of slits oriented longitudinally along a longitudinal axis of the outer sleeve, the plurality of slits having a first group of slits and a second group of slits, wherein the first group of slits and the second group of slits are staggered around a circumference of the outer sleeve, and each of the plurality of slits spanning less than half of the length without extending to either a proximal end or a distal end of the outer sleeve; anda radially expandable support layer partially encapsulated between the inner tube and the outer sleeve, wherein the support layer comprises a plurality of individual ring stents having a zigzag pattern defining alternating peaks and valleys, and wherein the plurality of slits of the outer sleeve are aligned over the peaks in the zigzag pattern of ring stents of the support layer.
  • 2. The implantable medical device according to claim 1, comprising a proximal unslitted region having a length in a range of 5 mm to 10 mm.
  • 3. The implantable medical device according to claim 1, further comprising a distal unslitted region having a length in a range of 5 mm to 10 mm.
  • 4. The implantable medical device according to claim 1, wherein each of the plurality of slits has an approximately equivalent length.
PRIORITY

This application is a division of U.S. patent application Ser. No. 13/023,403, filed Feb. 8, 2011, now U.S. Pat. No. 8,617,337, which is a division of U.S. patent application Ser. No. 12/538,361, filed Aug. 10, 2009, now U.S. Pat. No. 7,914,639, which is a division of U.S. patent application Ser. No. 10/873,062, filed Jun. 21, 2004, now abandoned, which is a division of U.S. patent application Ser. No. 09/848,740, filed May 3, 2001, now U.S. Pat. No. 6,770,087, which is a division of U.S. patent application Ser. No. 09/388,496, filed Sep. 2, 1999, now U.S. Pat. No. 6,398,803, which claims the benefit of U.S. Provisional Patent Application No. 60/118,269, filed Feb. 2, 1999. This application expressly incorporates by reference the entirety of each of the above-mentioned applications as if fully set forth herein.

US Referenced Citations (350)
Number Name Date Kind
612897 Ellis Oct 1898 A
1505591 Goldfarb Feb 1924 A
2642625 Peck Jun 1953 A
3027601 Barry Apr 1962 A
3060517 Fields Oct 1962 A
3105492 Jeckel Oct 1963 A
3196194 Ely, Jr. et al. Jul 1965 A
3207601 Barry Sep 1965 A
3281511 Goldsmith Oct 1966 A
3304557 Polansky Feb 1967 A
3657744 Ersek Apr 1972 A
3767500 Tally et al. Oct 1973 A
3887761 Gore Jun 1975 A
3992725 Homsy Nov 1976 A
4061517 Dutton, III et al. Dec 1977 A
4159370 Koizumi et al. Jun 1979 A
4324574 Fagan Apr 1982 A
RE31341 Koizumi et al. Aug 1983 E
4416028 Eriksson et al. Nov 1983 A
RE31618 Mano et al. Jul 1984 E
4482516 Bowman et al. Nov 1984 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4580568 Gianturco Apr 1986 A
4588461 Braun May 1986 A
4596837 Yamamoto et al. Jun 1986 A
4604762 Robinson Aug 1986 A
4629458 Pinchuk Dec 1986 A
4647416 Seiler, Jr. et al. Mar 1987 A
4655769 Zachariades Apr 1987 A
4665906 Jervis May 1987 A
4714748 Hoashi et al. Dec 1987 A
4731073 Robinson Mar 1988 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4747849 Galtier May 1988 A
4760102 Moriyama et al. Jul 1988 A
4767418 Deininger et al. Aug 1988 A
4776337 Palmaz Oct 1988 A
4816339 Tu et al. Mar 1989 A
4820298 Leveen et al. Apr 1989 A
4830062 Yamamoto et al. May 1989 A
4850999 Planck Jul 1989 A
4857069 Kira Aug 1989 A
4886062 Wiktor Dec 1989 A
4907336 Gianturco Mar 1990 A
4922905 Strecker et al. May 1990 A
4935068 Duerig Jun 1990 A
4954126 Wallsten et al. Sep 1990 A
4955899 Della Coma et al. Sep 1990 A
4957669 Primm Sep 1990 A
4969458 Wiktor Nov 1990 A
4969896 Shors Nov 1990 A
5019090 Pinchuk May 1991 A
5061275 Wallsten et al. Oct 1991 A
5061276 Tu et al. Oct 1991 A
5064435 Porter Nov 1991 A
5067957 Jervis Nov 1991 A
5071609 Tu et al. Dec 1991 A
5078726 Kreamer Jan 1992 A
5078736 Behl Jan 1992 A
5084065 Weldon et al. Jan 1992 A
5102417 Palmaz Apr 1992 A
5116360 Pinchuk et al. May 1992 A
5116365 Hillstead May 1992 A
5122154 Rhodes Jun 1992 A
5123917 Lee Jun 1992 A
5124523 Oehlmann et al. Jun 1992 A
5133732 Wiktor Jul 1992 A
5135503 Abrams Aug 1992 A
5139480 Hickle et al. Aug 1992 A
5143085 Wilson Sep 1992 A
5152782 Kowligi et al. Oct 1992 A
5156620 Pigott Oct 1992 A
5158548 Lau et al. Oct 1992 A
5163951 Pinchuk et al. Nov 1992 A
5167614 Tessmann et al. Dec 1992 A
5171805 Tatemoto et al. Dec 1992 A
5192307 Wall Mar 1993 A
5195984 Schatz Mar 1993 A
5211658 Clouse May 1993 A
5219355 Parodi et al. Jun 1993 A
5219361 von Recum et al. Jun 1993 A
5231989 Middleman et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5234739 Tanaru et al. Aug 1993 A
5236446 Dumon Aug 1993 A
5236447 Kubo et al. Aug 1993 A
5242399 Lau et al. Sep 1993 A
5258027 Berghaus et al. Nov 1993 A
5282823 Schwartz et al. Feb 1994 A
5282824 Gianturco Feb 1994 A
5282847 Trescony et al. Feb 1994 A
5282848 Schmitt Feb 1994 A
5282849 Kolff et al. Feb 1994 A
5282860 Matsuno et al. Feb 1994 A
5316023 Palmaz et al. May 1994 A
5330500 Song et al. Jul 1994 A
5334201 Cowan Aug 1994 A
5341818 Abrams et al. Aug 1994 A
5344426 Lau et al. Sep 1994 A
5349964 Imran et al. Sep 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5354329 Whalen Oct 1994 A
5360443 Barone et al. Nov 1994 A
5366504 Andersen et al. Nov 1994 A
5370681 Herweck et al. Dec 1994 A
5370691 Samson Dec 1994 A
5376110 Tu et al. Dec 1994 A
5382261 Palmaz Jan 1995 A
5383106 Yoshida et al. Jan 1995 A
5383892 Cardon et al. Jan 1995 A
5383926 Lock et al. Jan 1995 A
5383928 Scott et al. Jan 1995 A
5384019 Keating et al. Jan 1995 A
5385580 Schmitt Jan 1995 A
5387235 Chuter Feb 1995 A
5387236 Noishiki et al. Feb 1995 A
5389106 Tower Feb 1995 A
5395390 Simon et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5405378 Strecker et al. Apr 1995 A
5411476 Abrams et al. May 1995 A
5421955 Lau et al. Jun 1995 A
5429869 McGregor et al. Jul 1995 A
5433996 Kranzler et al. Jul 1995 A
5437083 Williams et al. Aug 1995 A
5443496 Schwartz et al. Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5452726 Burmeister et al. Sep 1995 A
5458615 Klemm et al. Oct 1995 A
5464438 Menaker Nov 1995 A
5464440 Johansson et al. Nov 1995 A
5464449 Ryan et al. Nov 1995 A
5474563 Myler et al. Dec 1995 A
5489295 Piplani et al. Feb 1996 A
5496364 Schmitt Mar 1996 A
5500013 Buscemi et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5507769 Marin et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5514115 Frantzen et al. May 1996 A
5514154 Lau et al. May 1996 A
5522881 Lentz Jun 1996 A
5522883 Slater et al. Jun 1996 A
5523092 Hanson et al. Jun 1996 A
5527353 Schmitt Jun 1996 A
5527355 Ahn Jun 1996 A
5540712 Kleshinski et al. Jul 1996 A
5540713 Schnepp-Pesch et al. Jul 1996 A
5546646 Williams et al. Aug 1996 A
5549635 Solar Aug 1996 A
5549663 Cottone, Jr. Aug 1996 A
5554181 Das Sep 1996 A
5556389 Liprie Sep 1996 A
5556413 Lam Sep 1996 A
5556414 Turi Sep 1996 A
5556426 Popadiuk et al. Sep 1996 A
5562725 Schmitt et al. Oct 1996 A
5569295 Lam Oct 1996 A
5571170 Palmaz et al. Nov 1996 A
5571171 Barone et al. Nov 1996 A
5571173 Parodi et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5591197 Orth et al. Jan 1997 A
5591222 Susawa et al. Jan 1997 A
5591223 Lock et al. Jan 1997 A
5591224 Schwartz et al. Jan 1997 A
5591228 Edoga Jan 1997 A
5591229 Parodi et al. Jan 1997 A
5591288 Becker et al. Jan 1997 A
5593417 Rhodes Jan 1997 A
5597378 Jervis Jan 1997 A
5603721 Lau et al. Feb 1997 A
5607445 Summers Mar 1997 A
5607478 Lentz et al. Mar 1997 A
5609624 Kalis Mar 1997 A
5620763 House et al. Apr 1997 A
5628786 Banas et al. May 1997 A
5628788 Pinchuk May 1997 A
5630806 Inagaki et al. May 1997 A
5630829 Lauterjung May 1997 A
5630840 Mayer May 1997 A
5632840 Campbell May 1997 A
5639278 Dereume et al. Jun 1997 A
5645559 Hachtman et al. Jul 1997 A
5649950 Bourne et al. Jul 1997 A
5649977 Campbell Jul 1997 A
5653727 Wiktor Aug 1997 A
5653747 Dereume et al. Aug 1997 A
5665117 Rhodes Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674241 Bley et al. Oct 1997 A
5674277 Freitag Oct 1997 A
5676671 Inoue et al. Oct 1997 A
5681345 Euteneuer Oct 1997 A
5683448 Cragg Nov 1997 A
5683453 Palmaz Nov 1997 A
5693085 Buirge et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5700285 Myers et al. Dec 1997 A
5700286 Tartaglia et al. Dec 1997 A
5713949 Jayaraman et al. Feb 1998 A
5716393 Lindenberg et al. Feb 1998 A
5718159 Thompson Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5719873 Yamashita et al. Feb 1998 A
5723003 Winston et al. Mar 1998 A
5723004 Dereume et al. Mar 1998 A
5728131 Frantzen et al. Mar 1998 A
5728158 Lau et al. Mar 1998 A
5735892 Myers et al. Apr 1998 A
5735893 Lau et al. Apr 1998 A
5738674 Williams et al. Apr 1998 A
5749880 Banas et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755774 Pinchuk May 1998 A
5755781 Jayaraman et al. May 1998 A
5766238 Lau et al. Jun 1998 A
5769817 Burgmeier Jun 1998 A
5769884 Solovay Jun 1998 A
5776161 Globerman et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5788626 Thompson Aug 1998 A
5800512 Lentz et al. Sep 1998 A
5810870 Myers et al. Sep 1998 A
5824037 Fogarty et al. Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824046 Smith et al. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824054 Khosravi et al. Oct 1998 A
5843161 Solovay Dec 1998 A
5843166 Lentz et al. Dec 1998 A
5849037 Frid et al. Dec 1998 A
5851232 Lois Dec 1998 A
5863366 Snow Jan 1999 A
5871536 Lazarus Feb 1999 A
5871537 Holman et al. Feb 1999 A
5873906 Lau et al. Feb 1999 A
5876448 Thompson et al. Mar 1999 A
5897588 Hull Apr 1999 A
5919225 Lau et al. Jul 1999 A
5925061 Ogi et al. Jul 1999 A
5928279 Shannon et al. Jul 1999 A
5961545 Lentz et al. Oct 1999 A
5968070 Bley et al. Oct 1999 A
5968091 Pinchuk et al. Oct 1999 A
6001125 Golds et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6010529 Herweck et al. Jan 2000 A
6010530 Goicoechea Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6036724 Lentz et al. Mar 2000 A
6039755 Edwin et al. Mar 2000 A
6042605 Martin et al. Mar 2000 A
6048484 House et al. Apr 2000 A
6053943 Edwin et al. Apr 2000 A
6063111 Hieshima et al. May 2000 A
6090127 Globerman Jul 2000 A
6120535 McDonald et al. Sep 2000 A
6124523 Banas et al. Sep 2000 A
6139573 Sogard et al. Oct 2000 A
6149681 Houser et al. Nov 2000 A
6156062 McGuinness Dec 2000 A
6165210 Lau et al. Dec 2000 A
6214039 Banas et al. Apr 2001 B1
6264684 Banas et al. Jul 2001 B1
6306141 Jervis Oct 2001 B1
6309343 Lentz et al. Oct 2001 B1
6309413 Dereume et al. Oct 2001 B1
6312454 Stockel et al. Nov 2001 B1
6364903 Tseng et al. Apr 2002 B2
6364904 Smith Apr 2002 B1
6375787 Lukic et al. Apr 2002 B1
6379379 Wang Apr 2002 B1
6383214 Banas et al. May 2002 B1
6398803 Layne et al. Jun 2002 B1
6451047 McCrea et al. Sep 2002 B2
6451052 Burmeister et al. Sep 2002 B1
6488701 Nolting et al. Dec 2002 B1
6497671 Ferrera et al. Dec 2002 B2
6524334 Thompson Feb 2003 B1
6547814 Edwin et al. Apr 2003 B2
6579314 Lombardi et al. Jun 2003 B1
6585760 Fogarty Jul 2003 B1
6673103 Golds et al. Jan 2004 B1
6673105 Chen Jan 2004 B1
6733524 Tseng et al. May 2004 B2
6740115 Lombardi et al. May 2004 B2
6758858 McCrea et al. Jul 2004 B2
6770086 Girton Aug 2004 B1
6770087 Layne et al. Aug 2004 B2
6786920 Shannon et al. Sep 2004 B2
6790225 Shannon et al. Sep 2004 B1
6790226 Edwin et al. Sep 2004 B2
6797217 McCrea et al. Sep 2004 B2
6808533 Goodwin et al. Oct 2004 B1
7060150 Banas et al. Jun 2006 B2
7083640 Lombardi et al. Aug 2006 B2
7288111 Holloway et al. Oct 2007 B1
7306756 Edwin et al. Dec 2007 B2
7462190 Lombardi Dec 2008 B2
7578899 Edwin et al. Aug 2009 B2
7914639 Layne et al. Mar 2011 B2
7939000 Edwin et al. May 2011 B2
8137605 McCrea et al. Mar 2012 B2
8157940 Edwin et al. Apr 2012 B2
8196279 Schlun Jun 2012 B2
8337650 Edwin et al. Dec 2012 B2
8585753 Scanlon Nov 2013 B2
8617337 Layne et al. Dec 2013 B2
8617441 Edwin et al. Dec 2013 B2
8647458 Banas et al. Feb 2014 B2
20010010012 Edwin et al. Jul 2001 A1
20010021870 Edwin et al. Sep 2001 A1
20010032009 Layne et al. Oct 2001 A1
20010039446 Edwin et al. Nov 2001 A1
20020040237 Lentz et al. Apr 2002 A1
20030004559 Lentz et al. Jan 2003 A1
20030006528 Edwin et al. Jan 2003 A1
20030144725 Lombardi Jul 2003 A1
20030191519 Lombardi et al. Oct 2003 A1
20030201058 Banas et al. Oct 2003 A1
20040024442 Sowinski et al. Feb 2004 A1
20040162603 Golds et al. Aug 2004 A1
20040162604 Sowinski et al. Aug 2004 A1
20040181278 Tseng et al. Sep 2004 A1
20040204757 Lombardi et al. Oct 2004 A1
20040232588 Edwin et al. Nov 2004 A1
20040236400 Edwin et al. Nov 2004 A1
20040236402 Layne et al. Nov 2004 A1
20050055081 Goodwin et al. Mar 2005 A1
20050060020 Jenson Mar 2005 A1
20050096737 Shannon et al. May 2005 A1
20050113909 Shannon et al. May 2005 A1
20050131515 Cully et al. Jun 2005 A1
20050131527 Pathak Jun 2005 A1
20060201609 Edwin et al. Sep 2006 A1
20060229714 Lombardi et al. Oct 2006 A1
20070207186 Scanlon et al. Sep 2007 A1
20090125092 McCrea et al. May 2009 A1
20090294035 Layne et al. Dec 2009 A1
20090311132 Banas et al. Dec 2009 A1
20110196473 McCrea et al. Aug 2011 A1
20120145318 McCrea et al. Jun 2012 A1
20120193018 Banas et al. Aug 2012 A1
20130102839 Banas et al. Apr 2013 A1
20140096906 Edwin et al. Apr 2014 A1
20140107766 Banas et al. Apr 2014 A1
Foreign Referenced Citations (66)
Number Date Country
2215027 Sep 1996 CA
03918736 Dec 1990 DE
19524653 Jun 1996 DE
0146794 Jul 1985 EP
0146794 Jul 1985 EP
0221570 May 1987 EP
0221570 May 1987 EP
0335341 Oct 1989 EP
0335341 Oct 1989 EP
0461791 Dec 1991 EP
0461791 Dec 1991 EP
0551179 Jul 1993 EP
0551179 Jul 1993 EP
0603959 Jun 1994 EP
0646365 Apr 1995 EP
0646365 Apr 1995 EP
0648869 Apr 1995 EP
0648869 Apr 1995 EP
0656196 Jun 1995 EP
0656196 Jun 1995 EP
0662307 Jul 1995 EP
0662307 Jul 1995 EP
0667132 Aug 1995 EP
0667132 Aug 1995 EP
0689805 Jan 1996 EP
0689806 Jan 1996 EP
0716835 Jun 1996 EP
0730848 Sep 1996 EP
0734698 Oct 1996 EP
0747022 Dec 1996 EP
0749729 Dec 1996 EP
0749729 Dec 1996 EP
0792627 Sep 1997 EP
0814729 Jan 1998 EP
0893108 Jan 1999 EP
2671482 Jul 1992 FR
1505591 Mar 1978 GB
2281865 Mar 1995 GB
2002510985 Apr 2002 JP
1994012136 Jun 1994 WO
1994013224 Jun 1994 WO
1994024961 Nov 1994 WO
9505277 Feb 1995 WO
1995005132 Feb 1995 WO
1995005555 Feb 1995 WO
1996000103 Jan 1996 WO
9612517 May 1996 WO
199511817 Jul 1996 WO
9622745 Aug 1996 WO
9625897 Aug 1996 WO
1996028115 Sep 1996 WO
9633066 Oct 1996 WO
9637165 Nov 1996 WO
9640000 Dec 1996 WO
1997007751 Mar 1997 WO
1997021401 Jun 1997 WO
1997021403 Jun 1997 WO
1998000090 Jan 1998 WO
1998026731 Jun 1998 WO
1998031305 Jul 1998 WO
1998031306 Jul 1998 WO
1998313305 Jul 1998 WO
1998038947 Sep 1998 WO
WO 9925252 May 1999 WO
2000045742 Aug 2000 WO
9510700 Nov 1996 ZA
Non-Patent Literature Citations (63)
Entry
U.S. Appl. No. 12/546,483, filed Aug. 24, 2009 Final Office Action dated Oct. 20, 2011.
U.S. Appl. No. 12/546,483, filed Aug. 24, 2009 Non-Final Office Action dated Jun. 23, 2011.
U.S. Appl. No. 13/023,403, filed Feb. 8, 2011 Final Office Action dated Jul. 16, 2013.
U.S. Appl. No. 13/023,403, filed Feb. 8, 2011 Non-Final Office Action dated Apr. 27, 2012.
U.S. Appl. No. 13/023,403, filed Feb. 8, 2011 Non-Final Office Action dated Nov. 23, 2012.
U.S. Appl. No. 13/088,129, filed Apr. 15, 2011 Non-Final Office Action dated Jun. 29, 2011.
U.S. Appl. No. 13/399,715, filed Feb. 17, 2012 Final Office Action dated Jul. 3, 2013.
U.S. Appl. No. 13/399,715, filed Feb. 17, 2012 Non-Final Office Action dated Feb. 22, 2013.
U.S. Appl. No. 13/434,472, filed Mar. 29, 2012 Non-Final Office Action dated Jun. 8, 2012.
U.S. Appl. No. 13/434,472, filed Mar. 29, 2012 Notice of Allowance dated Sep. 20, 2012.
U.S. Appl. No. 13/715,874, filed Dec. 14, 2012 Non-Final Office Action dated May 9, 2013.
Villani, V., “A Study on the Thermal Behaviour and Structural Characteristics of Polytetrafluoroethylene,” Thermochimica Acta, 162:189-193 (1990).
Association for the Advancement of Medical Instrumentation, “Cardiovascular implants—Vascular prostheses” ANSI/AMI vol. 20. (1994).
Briskman, et al., “A Study of the Crystallinity of Polytetrafluoroethylene by X-Ray Diffraction Analysis and Differential Scanning Calorimetry,” Vysokomol. Soedin , Kratk. Soobshcheniya. vol. 31, No. 7, pp. 539-543. 1989.
Chuter, T., “Bifurcated endovascular graft insertion for abdominal aortic aneurysm” Vascular and Endovascular Surgical Techniques, An Atlas Third Edition, pp. 92-99 (1994).
Cragg, A. and Dake, M., “Persutaneous Femoropopliteal Graft Placement,” Interventional Radiology 187(30: 643-648 (Jun. 1993).
Dietrich, E. and Papazoglou, K. Endoluminal Grafting for Aneurysmal and Occlusive Disease in the Superficial Femoral Artery: Early Experience, J. Endovase Surgery, 2:225-239( Aug. 1995).
Dorros et al., “Closure of a Popliteal Arteriovenous Fistula Using an Autologous Vein-Covered Palmaz Stent,” J Endovasc Surgery, 2:177-181 (May 1995).
Heuser et al.,“Endoluminal Grafting for Percutaneous Aneurysm Exclusion in an Aortocoronary Saphenous Vein Graft: The First Clinical Experience,” J Endovasc Surgery, 2:81-88 (Feb. 1995).
Hu, T., “Characterization of the crystallinity of polytetrafluoroethylene by X-ray and IR spectroscopy, differential scanning calorimetry, viscoelastic spectroscopy and the use of a density gradient tube,” Wear, 82:369-376 (1982).
Khanna et al. “A New Differential Scanning Calorimetry based Approach for the Estimation of Thermal Conductivity of Polymer solids and Melts,” Polymer Engineering and Science, 28(16):1034-1041 (1988).
Khanna, Y.P., “The melting temperature of polytetrafluoroethylene,” Journal of Materials Science Letters, 7(8):817-818 (1988).
Lau et al., “Glass Transition of Poly(tetrafluoroethylene),” Macromolecules 17:1102-1104 (1984).
Lau et al., “The Thermodynamic Properties of Polytetrafluoroethylene,” Journal of Polymer Science: Polymer Physics Edition, 22:379-405 (1984).
Marin et al., “Transluminally placed endovascular stented graft repair for arterial trauma,” The Journal of Vascular Surgery on Compact Disc, 18(6): 11 unnumbered pages (Sep. 1994).
Marin, M.L. and Veith, F. J., “Endoluminal stented graft aorto-bifemoral reconstruction,” Vascular and Endovascular Surgical Techniques. 3rd Edition, R. M. Greenhalgh ed., W. B. Saunders Company Ltd.: Philadelphia, pp. 100-104 (1994).
Marston et al., “Transbrachial Endovascular Exclusion of an Axillary Artery Pseudoaneurysm with PTFE-Covered Stents,” J. Endovasc Surgery, 2:172-176 (May 1995).
May et al. “Transluminal placement of a prosthetic graft-stent device for treatment of subclavian artery aneurysm,” Journal of Vascular Surgery, 18(6):1056-1059. Dec. 1993.
McClurken et al., “Physical Properties and Test Methods for Expanded Polytetrafluoroethylene (PTFE) Grafts,” American Society for Testing and Materials, 86-14077 pp. 82-93 (1984).
Moore, W., “Transfemoral endovascular repair of abdominal aortic aneurysm using the endovascular graft system device,” Vascular and Endovascular Surgical Techniques. 3rd Edition, R. M. Greenhalgh ed., W. B. Saunders Company Ltd.: Philadelphia, pp. 78-91 (1994).
Palmaz et al. “Uses of balloon expandable stents in combination with PTFE,” Vascular and Endovascular Surgical Techniques, an Atlas, Third Edition, pp. 36-42 (1994).
Palmaz et al., “Use of Stents Covered With Polytetrafluoroethylene in Experimental Abdominal Aortic Aneurysm,” Journal of Vascular and Interventional Radiology, 6(6): 879-885 (Nov. 1995).
Palmaz et al.,“Physical Properties of Polytetrafluoroethylene Bypass Material After Balloon Dilation,” Journal of Vascular and Interventioanl Radiology, 7(5):657-663 (Sep. 1996).
Papazoglou et al., “International Congress VIII on Endovascular Interventions” J Endovasc Surg, 2:89-129 (Feb. 1995).
Parodi, J., “Transfemoral intraluminal graft implantation for abdominal aortic aneurysms,” Annals of Vascular Surgery, 5(6):491-499 (1991).
PCT/US2000/02884 filed Feb. 2, 2000 International Preliminary Examination Report dated Aug. 27, 2002.
PCT/US2000/02884 filed Feb. 2, 2000 International Seach Report dated Jul. 10, 2000.
Shapiro, M. and Levin, D., “Percutaneous Femoropopliteal Graft Placement: Is This the Next Step?” Radiology 187(30: 618-619 (Jun. 1993).
Starkweather, H. W. Jr., “The Density of Amorphous Polytetrafluoroethylene,” Journal of Polymer Science: Polymer Physics Editions, 20:2159-2161 (1982).
U.S. Appl. No. 09/858,035, filed May 15, 2001 Advisory Action dated Oct. 7, 2003.
U.S. Appl. No. 09/858,035, filed May 15, 2001 Final Office Action dated Jul. 25, 2003.
U.S. Appl. No. 09/858,035, filed May 15, 2001 Non-Final Office Action dated Dec. 1, 2003.
U.S. Appl. No. 09/858,035, filed May 15, 2001 Non-Final Office Action dated Oct. 1, 2002.
U.S. Appl. No. 10/242,160, filed Sep. 12, 2002 Non-Final Office Action dated Oct. 27, 2003.
U.S. Appl. No. 10/431,685, filed May 8, 2003 Non-Final Office Action dated Jun. 28, 2005.
U.S. Appl. No. 10/836,492, filed Apr. 30, 2004 Final Office Action dated Nov. 23, 2005.
U.S. Appl. No. 10/836,492, filed Apr. 30, 2004 Non-Final Office Action dated Jun. 8, 2005.
U.S. Appl. No. 10/873,062, filed Jun. 21, 2004 Final Office Action dated Apr. 28, 2008.
U.S. Appl. No. 10/873,062, filed Jun. 21, 2004 Final Office Action dated Jun. 3, 2009.
U.S. Appl. No. 10/873,062, filed Jun. 21, 2004 Non-Final Office Action dated Dec. 18, 2007.
U.S. Appl. No. 10/873,062, filed Jun. 21, 2004 Non-Final Office Action dated Oct. 2, 2008.
U.S. Appl. No. 10/873,514, filed Jun. 21, 2004 Non-Final Office Action dated Jan. 23, 2007.
U.S. Appl. No. 11/429,849, filed May 8, 2006 Final Office Action dated Mar. 11, 2009.
U.S. Appl. No. 11/429,849, filed May 8, 2006 Final Office Action dated Oct. 15, 2008.
U.S. Appl. No. 11/447,626, filed Jun. 6, 2006 Final Office Action dated Nov. 14, 2008.
U.S. Appl. No. 11/447,626, filed Jun. 6, 2006 Non-Final Office Action dated Apr. 16, 2008.
U.S. Appl. No. 11/447,626, filed Jun. 6, 2006 Non-Final Office Action dated Sep. 13, 2007.
U.S. Appl. No. 12/272,411, filed Nov. 17, 2008 Final Office Action dated Mar. 9, 2011.
U.S. Appl. No. 12/272,411, filed Nov. 17, 2009 Non-Final Office Action dated Oct. 4, 2010.
U.S. Appl. No. 12/538,361, filed Aug. 10, 2009 Final Office Action dated Sep. 10, 2010.
U.S. Appl. No. 12/538,361, filed Aug. 10, 2009 Non-Final Office Action dated May 26, 2010.
U.S. Appl. No. 12/538,361, filed Aug. 10, 2009 Notice of Allowance dated Dec. 2, 2010.
EP 06112834.4 Extended European Search Report dated Apr. 8, 2014.
Related Publications (1)
Number Date Country
20140107763 A1 Apr 2014 US
Provisional Applications (1)
Number Date Country
60118269 Feb 1999 US
Divisions (5)
Number Date Country
Parent 13023403 Feb 2011 US
Child 14104893 US
Parent 12538361 Aug 2009 US
Child 13023403 US
Parent 10873062 Jun 2004 US
Child 12538361 US
Parent 09848740 May 2001 US
Child 10873062 US
Parent 09388496 Sep 1999 US
Child 09848740 US